Literature DB >> 32366577

The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes.

Olesya L Ilkun1, Tom Greene2, Alfred K Cheung1,3, Paul K Whelton4, Guo Wei1,2, Robert E Boucher1, Walter Ambrosius5, Glenn M Chertow6, Srinivasan Beddhu7,3.   

Abstract

OBJECTIVE: To examine whether low baseline diastolic blood pressure (DBP) modifies the effects of intensive systolic blood pressure (SBP) lowering on cardiovascular outcomes in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: The Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial (ACCORD BP), a two-by-two factorial randomized controlled trial, examined effects of SBP (<120 vs. <140 mmHg) and glycemic (HbA1c <6% vs. 7.0-7.9% [<42 vs. 53-63 mmol/mol]) control on cardiovascular events in T2DM (N = 4,731). We examined whether effects of SBP control on cardiovascular composite were modified by baseline DBP and glycemic control.
RESULTS: Intensive SBP lowering decreased the risk of the cardiovascular composite (hazard ratio [HR] 0.76 [95% CI 0.59-0.98]) in the standard glycemic arm but not in the intensive glycemic arm (HR 1.06 [95% CI 0.81-1.40]). Spline regression models relating the effects of the intervention on the cardiovascular composite across the range of baseline DBP did not show evidence of effect modification by low baseline DBP for the cardiovascular composite in the standard or intensive glycemic arms. The relation between the effect of the intensive SBP intervention and baseline DBP was similar between glycemic arms for the cardiovascular composite three-way interaction (P = 0.83).
CONCLUSIONS: In persons with T2DM, intensive SBP lowering decreased the risk of cardiovascular composite end point irrespective of baseline DBP in the setting of standard glycemic control. Hence, low baseline DBP should not be an impediment to intensive SBP lowering in patients with T2DM treated with guideline-recommended standard glycemic control.
© 2020 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32366577      PMCID: PMC7372050          DOI: 10.2337/dc19-2047

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  26 in total

1.  Excess Mortality among Persons with Type 2 Diabetes.

Authors:  Mauro Tancredi; Annika Rosengren; Ann-Marie Svensson; Mikhail Kosiborod; Aldina Pivodic; Soffia Gudbjörnsdottir; Hans Wedel; Mark Clements; Sofia Dahlqvist; Marcus Lind
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

Review 2.  The J-Curve Phenomenon in Hypertension.

Authors:  Yuan-Yuan Kang; Ji-Guang Wang
Journal:  Pulse (Basel)       Date:  2016-06-17

3.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.

Authors:  Emmanuelle Vidal-Petiot; Ian Ford; Nicola Greenlaw; Roberto Ferrari; Kim M Fox; Jean-Claude Tardif; Michal Tendera; Luigi Tavazzi; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Lancet       Date:  2016-08-30       Impact factor: 79.321

4.  Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?

Authors:  Franz H Messerli; Giuseppe Mancia; C Richard Conti; Ann C Hewkin; Stuart Kupfer; Annette Champion; Rainer Kolloch; Athanase Benetos; Carl J Pepine
Journal:  Ann Intern Med       Date:  2006-06-20       Impact factor: 25.391

5.  Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.

Authors:  John W McEvoy; Yuan Chen; Andreea Rawlings; Ron C Hoogeveen; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin
Journal:  J Am Coll Cardiol       Date:  2016-08-30       Impact factor: 24.094

6.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

7.  Effects of combination lipid therapy in type 2 diabetes mellitus.

Authors:  Henry N Ginsberg; Marshall B Elam; Laura C Lovato; John R Crouse; Lawrence A Leiter; Peter Linz; William T Friedewald; John B Buse; Hertzel C Gerstein; Jeffrey Probstfield; Richard H Grimm; Faramarz Ismail-Beigi; J Thomas Bigger; David C Goff; William C Cushman; Denise G Simons-Morton; Robert P Byington
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

8.  J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.

Authors:  Sripal Bangalore; Franz H Messerli; Chuan-Chuan Wun; Andrea L Zuckerman; David DeMicco; John B Kostis; John C LaRosa
Journal:  Eur Heart J       Date:  2010-09-16       Impact factor: 29.983

9.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

10.  Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study.

Authors:  Samuel Adamsson Eryd; Soffia Gudbjörnsdottir; Karin Manhem; Annika Rosengren; Ann-Marie Svensson; Mervete Miftaraj; Stefan Franzén; Staffan Björck
Journal:  BMJ       Date:  2016-08-04
View more
  5 in total

1.  Development and validation of a nomogram based on the hospital information system for quantitative assessment of the risk of cardiocerebrovascular complications of diabetes.

Authors:  Xin Xi; Guizhi Yin; Xiaoyong Wang; Xuesong Li
Journal:  Ann Transl Med       Date:  2022-06

2.  Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials.

Authors:  Chao Li; Kangyu Chen; Guoshuai Shi; Rui Shi; Zhenqiang Wu; Xiaodan Yuan; Vicky Watson; Zhixin Jiang; Hui Mai; Tian Yang; Duolao Wang; Tao Chen
Journal:  BMC Med       Date:  2022-06-20       Impact factor: 11.150

3.  Diastolic Blood Pressure and the J-Curve-Causal Effect or Confounding?

Authors:  Sydney E Hartsell; Srinivasan Beddhu
Journal:  JAMA Netw Open       Date:  2021-10-01

4.  Linear and Nonlinear Mendelian Randomization Analyses of the Association Between Diastolic Blood Pressure and Cardiovascular Events: The J-Curve Revisited.

Authors:  Alexis Battle; John W McEvoy; Marios Arvanitis; Guanghao Qi; Deepak L Bhatt; Wendy S Post; Nilanjan Chatterjee
Journal:  Circulation       Date:  2020-11-30       Impact factor: 29.690

5.  Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Systolic Blood Pressure Lowering on the Risk of Stroke.

Authors:  Saeed Shihab; Robert E Boucher; Nikita Abraham; Guo Wei; Srinivasan Beddhu
Journal:  Hypertension       Date:  2022-02-04       Impact factor: 9.897

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.